Comparability of 5 Alternative AAV9 Downstream Processes from Ultracentrifugation to Chromatography

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=atkGUfA1p9g

Improved analytical methods are helping improve the understanding of capsid heterogeneity in adeno-associated virus (AAV) therapeutic preparations. This understanding allows the development of manufacturing processes that produce AAV therapeutics with fewer non-functional capsids. • In this video, the speakers will present the results of a five-arm AAV9 comparability protocol that includes four alternative two-column downstream processes at 50-L scale and an ultracentrifugation (UC) process at 200-L scale. The UC process is the gold standard for functional capsid purification. • The expert speakers will outline simplified processes for both the capture and the empty/full (E/F) separation steps, including various combinations of cation exchange chromatography (CEX) and anion exchange chromatography (AEX) monoliths with different gradient types, as well as a process using an affinity resin and AEX monolith. • The speakers will also cover the analytical comparability of the drug substance lots, assessment of vector yields, host–cell proteins, plasmid and host-cell deoxyribonucleic acid (DNA) levels; capsid content by sedimentation-velocity analytical UC, charge detection mass spectrometry and mass photometry; vector protein purity by capillary electrophoresis; aggregation by size-exclusion chromatography; vector DNA purity by next-generation sequencing; potency by in vitro enhanced green fluorescent protein (eGFP) expression tests; and capsid protein charge heterogeneity and intact-capsid isoelectric point (pI) by capillary isoelectric focusing. • EXPLORE OUR AAV SOLUTIONS: • https://www.biaseparations.com/soluti... • OUR CIMmultus HR LINE: • https://www.biaseparations.com/soluti... • GET in TOUCH: • Webpage: https://www.biaseparations.com • E-mail: [email protected] • Tech support: [email protected]

#############################

New on site